Amit Bar-Or, MD, FRCPC - Can a Novel DMT Class Deliver Better Outcomes in MS? Considering the Potential of BTK Inhibition

Go online to PeerView.com/YAJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Optimal management of multiple sclerosis (MS) requires selecting medications that safely and effectively target different aspects of pathophysiology and offer choices in administration, risk/benefit balance, and patient adherence. Bruton tyrosine kinase (BTK) inhibitors are an emerging class of disease-modifying therapies that affect processes mediated by B cells and myeloid cells, which are contributors to the inflammation and neurodegeneration that drive MS. BTK inhibitors are a novel class in MS management with four agents currently in phase 3 trials. As such, clinicians must remain up to date with the latest data on the rationale for their use and trial findings on the efficacy, safety, and tolerability of this promising line of treatment. At a recent PeerView live event, MS experts shared relevant stories from their practice to highlight the rationale for the use of BTK inhibitors in MS, as well as perspectives on potential applications in clinical care and the latest data from clinical trials on BTK inhibition. Upon completion of this activity, participants should be better able to: Explain the rationale for investigating the potential of Bruton tyrosine kinase (BTK) inhibition in multiple sclerosis (MS) treatment; Assess emerging evidence on the risks and benefits associated with BTK inhibitors in late-stage clinical trials for the treatment of MS; and Identify patients who might be candidates for treatment with a BTK inhibitor, based on available data as well as individual patient characteristics and priorities]